FindTrial
Sign In

An international multi-centre open-label 2-arm phase III trial of adjuvant R435(bevacizumab) in "triple negative" breast cancer.

An international multi-centre open-label 2-arm phase III trial of adjuvant R435(bevacizumab) in "triple negative" breast cancer.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220555
Enrollment
Unknown
Registered
2008-05-12
Start date
2008-05-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

investigational material(s) Generic name etc : R435(Bevacizumab) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria -adult patients, >=18 years of age -operable primary invasive breast cancer -completed definitive loco-regional surgery -primary tumor centrally confirmed as triple negative Exclusion criteria -locally advanced breast cancers -previous breast cancer history -clinically significant cardiovascular disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Primary: Invasive disease-free survival—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026